Background {#Sec1}
==========

The prognosis of patients with gastric cancer remains dismal, although various treatment modalities have advanced in recent years \[[@CR1]\]. Clinically, 2-\[18F\] Fluoro-2-deoxy-D-glucose (^18^F-FDG) positron emission tomography/computed tomography (PET/CT) has been widely used in diagnosis, staging, restaging, therapy-response assessing, and prognosis predicting of patients with gastric cancers \[[@CR2]--[@CR4]\]. Especially, the volumetric parameters, like the metabolic tumor volume (MTV) and total lesion glycolysis (TLG), have shown advantages over the commonly used maximum standardized uptake value (SUV~max~) in predicting prognosis of patients with gastric cancer \[[@CR3], [@CR5], [@CR6]\].

The interaction between the c-MET (MET proto-oncogene, receptor tyrosine kinase) and its ligand, hepatocyte growth factor (HGF), is commonly related to tumorigenesis. Overexpression of c-MET has been reported as associated with poor prognosis in patients with gastric cancer \[[@CR7]--[@CR9]\]. Treatment targeting c-Met is a promising therapeutic approach for patients with c-MET-amplified gastric cancer. Indeed, phase III trials of onartuzumab and rilotumumab treatment of patients with gastric cancer overexpressing c-MET and a considerable number of phase I and phase II trials of agents targeting c-MET are ongoing \[[@CR10]--[@CR12]\]. Therefore, it is necessary to develop a method that can indicate c-MET expression to stratify patients. Until now, no study has investigated the correlation between FDG uptake and c-MET expression in gastric cancer.

In the present study, we attempted to investigate the prognostic value of semi-quantitative parameters on ^18^F-FDG PET/CT in patients with advanced gastric cancer undergoing chemotherapy. In addition, the associations between these parameters and c-MET positivity of gastric tumor in situ were also analyzed.

Methods {#Sec2}
=======

This study was approved by the Ethics Committee of Zhongshan Hospital of Fudan University (approval number: IRB2015--098) and was performed in accordance with the Helsinki Declaration of 1975, as revised in 2000. Written informed consent was obtained from all patients.

Study patients {#Sec3}
--------------

This study included and followed up 61 patients with advanced gastric cancer, who received various chemotherapies (including neoadjuvant chemotherapy, adjuvant chemotherapy, and palliative chemotherapy) between June 2011 and October 2016 in our hospital. The inclusion criteria were as follows: 1) All patients had pathologically confirmed gastric adenocarcinoma; 2) initial clinical staging reached advanced gastric cancer, which was inoperable; 3) the status of c-MET expression could be obtained using immunohistochemical staining; 4) all patients had received ^18^F-FDG PET/CT before chemotherapy. Patients with any of the following conditions were excluded: 1) They had a second primary malignant tumor; or 2) they had another death-threating illness. Clinicopathological information, including sex, age at diagnosis, pathological differentiation, Lauren classification, and baseline serum concentrations of carcinoembryonic antigen (CEA), cancer antigen (CA) 19--9, and CA 72--4, were documented.

PET/CT acquisition {#Sec4}
------------------

All patients fasted for about 6 h before PET/CT examination. Then, patients were injected with ^18^F-FDG (3.7 MBq/kg). The mean dose was 295.1 (range, 238.2--476.3) MBq. About one hour (mean ± standard deviation \[SD\], 63.1 ± 12.5 min) later, patients were suggested to drink water as much as possible, right after which PET/CT scanning were performed using a hybrid GE Discovery VCT 64 PET/CT scanner (General Electric, Milwaukee, WI, USA) from the proximal thigh to the skull base. Non-enhanced helical CT scanning was performed initially (200 mA, 120 kV, matrix 512 × 512, 0.8 s per rotation), and the CT images were reconstructed to a slice thickness of 1.5 mm for review. Thereafter, PET acquisition was performed (2 min/bed position) in three-dimensional mode, and images were reconstructed using ordered-subsets expectation maximization iterative reconstruction.

Imaging analysis {#Sec5}
----------------

Two physicians (A, G.L.; B, Y.H.), who each had worked for more than 3 years in department of nuclear medicine, evaluated the PET/CT images and measured the semi-quantitative parameters independently. First, patients were classified into two groups: Those with locoregional malignancy (including regional lymphadenopathy) and those with regional malignancy with distant metastasis, based on the PET/CT findings. Then, volumetric parameters of the tumors in situ were measured on an uWS-MI R001 workstation (United Imaging, Shanghai, China), according to the method described in a previous study \[[@CR5]\]. The isocontour method was used to create volume of interest (VOI) around the tumor. For lesions with SUV~max~ \> 2.5, a threshold of SUV ≥ 2.5 was used; however, for lesions with SUV~max~ ≤ 2.5, a 40% SUV~max~ threshold was used (Fig. [1](#Fig1){ref-type="fig"}). Each VOI generated a SUV~max~, a peak SUV (SUV~peak~), TLG (g), and MTV (mL). SUV~max~ was defined as the maximum SUV from a single pixel anywhere within the VOI, while SUV~peak~ was the highest mean SUV from a fixed 1-cm^3^ spherical VOI centered over the highest metabolic part of the tumor. MTV was defined as the sum of the metabolic volume above the predefined threshold, while TLG was defined as the product of the MTV and the mean SUV in the VOI. Observer A performed the measurements twice at an interval of over two months for testing reproducibility.Fig. 1PET/CT images illustrating tumor volume delineation of a typical gastric cancer. **a**, transverse PET image; **b**, transverse PET/CT fusion image; **c**, maximum intensity projection image. Circles in **a** and **b** denote volume of interest under a threshold of SUV ≥ 2.5. In addition, multiple metastases can be visualized in the liver (arrows). PET, positron emission tomography; CT, computed tomography; SUV~max~, maximum standardized uptake value; SUV~peak~, peak standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis

Pathological classification and c-MET expression assay {#Sec6}
------------------------------------------------------

Gastroscopy sampling during the initial diagnosis was used to evaluate tumor pathology and c-MET expression. Pathologically, the tumors were classified into well differentiated adenocarcinoma (WDA, including papillary adenocarcinoma and tubular adenocarcinoma), moderately differentiated adenocarcinoma (MDA), poorly differentiated adenocarcinoma (PDA), signet-ring cell carcinoma (SRC), and mucinous adenocarcinoma (MAC), according to the Japanese classification of gastric cancer \[[@CR13]\]. In addition, the tumors were classified into two microscopic growth types on the basis of the Lauren classification: Intestinal and non-intestinal. Diffuse, mixed, and unclassifiable types were included in non-intestinal type. Immunohistochemical staining for c-MET was performed according to the institutional standard process. According to a previous method \[[@CR14], [@CR15]\], the intensity of the membrane staining for c-MET was scored as follows: Score 0, no reactivity or less than 50% of tumor cells with any membranous reactivity; score 1+, 50% or more of tumor cells with weak membranous reactivity but less than 50% with moderate or higher membranous reactivity; score 2+, 50% or more of tumor cells with moderate or higher membranous reactivity but less than 50% with strong membranous reactivity; and score 3+, 50% or more of tumor cells with strong membranous reactivity. Membrane staining intensity with score of 2+ or 3+ was defined as c-MET positive.

Treatment and follow up {#Sec7}
-----------------------

Of the 61 included patients, 51 received neoadjuvant chemotherapy, then radical surgery, and adjuvant chemotherapy after surgery. The other 10 patients only received palliative chemotherapy. The chemotherapy regimen was one of the following: oxaliplatin and capecitabine; epirubicin, oxaliplatin and capecitabine; docetaxel, oxaliplatin, and 5-FU; oxaliplatin and 5-FU; docetaxel and oxaliplatin. According to the National Comprehensive Cancer Network guidelines \[[@CR16]\], all patients were followed up, including history taking, physical examination, serum tumor marker testing, abdominopelvic CT or magnetic resonance imaging (MRI) scanning, and gastroscopy. Patients were assessed every 3--4 months in the first 3 years and every 4--6 months, thereafter. Overall survival (OS) was the primary endpoint, which was defined as the time (in months) from the date of the baseline PET/CT scanning to the date when patients died from any cause. The secondary endpoint was progression-free survival (PFS), which was defined as the time (in months) from the date of the baseline PET/CT scanning to the date of confirmed progression. Progression was defined as at least a 20% increase in the sum of the diameters of lesions, according to the response evaluation criteria in solid tumor (RECIST 1.1). If progression was suspected, additional pathological diagnosis was performed to confirm it. Patients last known to be alive were censored at the date of last contact.

Statistical analysis {#Sec8}
--------------------

Inter-observer variabilities in the measurements on PET/CT between observer A and B, and intra-observer variabilities between the two measurement times performed by observer A were evaluated by calculating intraclass correlation coefficients (ICCs). An ICC greater than 0.75 indicated good agreement. Mean values recorded by the two observers were used for the final analysis. Clinicopathological characteristics of the patients and the semi-quantitative measurements on ^18^F-FDG PET/CT were compared between the c-MET positive and negative patients. Comparisons of categorical variables were performed using the chi-squared test and Fisher's exact test if there was any cell of the crosstab (a table indicating the relationship between two or more variables) that had an expected count less than five. Comparisons of continuous variables were conducted using Student's t test when a normal distribution was obtained using the Kolmogorov--Smirnov test, otherwise the Mann--Whitney U test was used. Kaplan--Meier survival analysis using the log-rank test was performed to compare PFS and OS between patient groups. The univariate and multivariate Cox proportional hazard regression were used to analyze the predictive values of the clinicopathological factors and PET parameters. All statistical analyses were performed on the statistical software SPSS 20 (IBM Corp., Armonk, NY, USA), with a two-sided *p* value less than 0.05 indicating a significance.

Results {#Sec9}
=======

Clinicopathological information {#Sec10}
-------------------------------

Of the 61 patients included, 41 (67.2%) were men and 20 (32.8%) were women, with a median age of 62 (range, 36--81) years. There were 33 (54.1%) patients with c-MET positive gastric cancers, while the tumors in 28 (45.9%) patients were c-MET negative. Comparisons of the clinicopathological information and findings on PET/CT are summarized in Table [1](#Tab1){ref-type="table"}. The distributions of patients' gender; age; baseline serum concentrations of CEA, CA19--9, and CA72--4; pathological type; and Lauren classification of the tumors in situ were not different between the c-MET-positive and negative patients, with *P* values all \> 0.05. Distant metastasis was also not associated with c-MET expression (*P* = 0.111). However, patients with c-MET-positive cancers had significantly shorter PFS (median in months: 11.5 vs. 17.6, *P* = 0.039) and OS (median in months: 17.0 vs. 24.3, *P* = 0.043) compared with those of patients with c-MET negative cancers.Table 1Comparisons of clinicopathological variables and semi-quantitative parameters on ^18^F-FDG PET/CT between c-Met positive and negative patientsVariablesNumber (*n* = 61)c-Met expression*P*-valuesPositiveNegativeGender Male41 (67.2%)20 (60.6%)21 (75.0%)0.233^†^ Female20 (32.8%)13 (39.4%)7 (25.0%)Median age (range)62 (36--81)61 (36--74)64 (38--81)0.541^\#^Pathological types WDA17 (27.9%)12 (36.4%)5 (17.9%)0.373† MDA18 (29.5%)9 (27.3%)9 (32.1%) PDA21 (34.4%)9 (27.3%)12 (42.9%) MAC/SRC5 (8.2%)3 (9.1%)2 (7.1%)Lauren classifications Intestinal23 (46.9%)13 (48.1%)10 (45.5%)0.851† Non-intestinal26 (53.1%)14 (51.9%)12 (54.5%)Baseline CEA (ng/ml) Median (range)2.9 (0.4--776.4)2.9 (0.4--776.4)3.1 (1.1--242.0)0.399^\#^Baseline CA19--9 (U/ml) Median (range)9.0 (0.6--597.4)8.4 (0.6--597.4)10.1 (0.6--69.2)0.510^\#^Baseline CA72--4 (U/ml) Median (range)2.8 (0.8--131.2)3.2 (0.8--131.2)2.0 (0.9--79.3)0.288^\#^Findings on PET/CT Locoregional26 (42.6%)11 (33.3%)15 (53.6%)0.111^†^ Distant metastasis35 (57.4%)22 (66.7%)13 (46.4%)SUV~max~ (mean ± SD)8.8 ± 6.409.6 ± 7.408.0 ± 4.910.335^\*^SUV~peak~ (mean ± SD)7.2 ± 5.227.7 ± 5.996.6 ± 4.080.438^\*^MTV (mL, mean ± SD)57.4 ± 54.3970.8 ± 53.1141.1 ± 52.320.034^\*^TLG (g, mean ± SD)328.2 ± 417.44428.4 ± 442.95205.7 ± 354.400.039^\*^PFS, Median (95%CI)14.5 (2.0--82.2)11.5 (7.8--15.2)17.6 (15.1--20.1)0.039^‡^OS, Median (95%CI)20.0 (5--86.2)17.0 (13.9--20.5)24.3 (17.0--31.6)0.043^‡^Note. *SD* standard deviation, *CA19--9* carbohydrate antigen 19--9, *CA72--4* carbohydrate antigen 72--4, *CEA* carcinoembryonic antigen, *WDA* well differentiated adenocarcinoma, *MDA* moderate differentiated adenocarcinoma, *PDA* poorly differentiated adenocarcinoma, *SRC* signet-ring cell carcinoma, *MAC* mucinous adenocarcinoma, *PET/CT* positron emission tomography/computed tomography, *SUV* standardized uptake value, *Max* maximum, *MTV* metabolic tumor volume, *TLG* total lesion glycolysis, *PFS* progression free survival, *OS* overall survival. \*, Student's t test; †, Chi square test; ‡, Kaplan-Meier analysis with the log-rank test; \#, Mann-Whitney U test

Associations of PET parameters with c-MET expression and with the presence of metastasis {#Sec11}
----------------------------------------------------------------------------------------

The intra- and inter-observer agreements of the measurements on PET/CT, expressed as ICCs, were good, with the former ranging from 0.818 for TLG to 0.907 for SUV~max~, and the latter ranging from 0.809 for TLG to 0.901 for SUV~max~ (Table [2](#Tab2){ref-type="table"}).Table 2Intra- and Inter-observer agreements among the semi-quantitative measurements on PET/CT, expressed as intraclass correlation coefficientsMeasurementsIntra-observer ICCInter-observer ICCSUV~max~0.907 (0.859--0.933)0.901 (0.810--0.914)SUV~peak~0.890 (0.837--0.922)0.884 (0.834--0.910)MTV0.831 (0.747--0.894)0.841 (0.732--0.896)TLG0.818 (0.733--0.887)0.809 (0.728--0.857)Note. *SUV* standardized uptake value, *Max* maximum, *MTV* metabolic tumor volume, *TLG* total lesion glycolysis, *ICC* intraclass correlation coefficient

The mean SUVmax and SUV~peak~ of the primary gastric cancers were 8.8 (SD, 6.40) and 7.2 (SD, 5.22); the mean MTV was 57.4 mL (SD, 54.39), and the mean TLG was 328.2 g (SD, 417.44). The SUV~max~ and SUV~mean~ values were not different between c-MET-positive and negative cancers (*P* = 0.335 and 0.438). However, the MTV and TLG values were significantly larger in patients with c-MET-positive cancers compared with those with c-MET-negative cancers (*P* = 0.034 and 0.039). None of these PET parameters was significantly different between patients with locoregional tumors and those with distant metastases (Table [3](#Tab3){ref-type="table"}).Table 3Correlations between presence of distant metastasis and PET parametersVariablesLocoregionalDistant metastasis*P*-valuesSUV~max~ (mean ± SD)8.3 ± 5.609.3 ± 6.960.555SUV~peak~ (mean ± SD)6.8 ± 4.777.5 ± 5.580.608MTV (ml, mean ± SD)59.4 ± 68.7256.0 ± 42.370.812TLG (g, mean ± SD)349.4 ± 514.37313.0 ± 339.190.742Note. *SD* standard deviation, *PET* positron emission tomography, *SUV* standardized uptake value, *Max* maximum, *MTV* metabolic tumor volume, *TLG* total lesion glycolysis

Survival outcomes in relation to parameters on PET according to c-MET expression status {#Sec12}
---------------------------------------------------------------------------------------

In the whole patient group, SUV~max~, SUV~peak~, MTV, and TLG were all significantly correlated with patient PFS (HR = 1.065, 1.079, 1.005, and 1.001, respectively; *P* = 0.004, 0.005, 0.031, and 0.031, respectively; Table [3](#Tab3){ref-type="table"}). SUV~max~ and SUV~peak~ correlated significantly with patient OS (HR = 1.059 and 1.071, respectively; *P* = 0.013 and 0.017, respectively; Table [4](#Tab4){ref-type="table"}). However, the correlations between the volumetric parameters (MTV and TLG) and OS were not significant (HR = 1.005 and 1.001, respectively; *P* = 0.055 and 0.072, respectively; Table [3](#Tab3){ref-type="table"}). Distant metastasis was significantly associated with PFS (HR = 5.009, *P* \<  0.001) and OS (HR = 3.236, *P* = 0.001).Table 4Univariate linear COX regression assessing associations between parameters from ^18^F-FDG PET/CT and patient prognosisVariablesPFSOSHR*P*HR*P*In all patients Gender  Male0.7440.3290.8830.695  Female^a^1.0001.000 Age (years)   ≥ 621.5060.1641.1430.660   \< 62^a^1.0001.000 Pathological types  WDA/MDA1.2520.4471.1030.749  PDA/MAC/SRC^a^1.0001.000 Lauren classifications  Intestinal0.9250.8090.8530.635  Non-intestinal^a^1.0001.000 Baseline CEA (ng/ml)   ≥ 2.91.1810.5761.6670.107   \< 2.9^a^1.0001.000 Baseline CA19--9 (U/ml)   ≥ 9.01.5370.1621.6320.138   \< 9.0^a^1.0001.000 Baseline CA72--4 (U/ml)   ≥ 2.81.8200.0851.2810.485   \< 2.8^a^1.0001.000 Findings on PET/CT  Distant metastasis5.009\<  0.0013.2360.001  Locoregional^a^1.0001.000 SUV~max~1.0650.0041.0590.013 SUV~peak~1.0790.0051.0710.017 MTV1.0050.0311.0050.055 TLG1.0010.0311.0010.072In c-Met positive patients SUV~max~1.0540.0371.0630.013 SUV~peak~1.0680.0341.0790.012 MTV1.0090.0131.0150.001 TLG1.0010.0121.0020.001In c-Met negative patients SUV~max~1.0550.1881.0130.775 SUV~peak~1.0710.1611.0150.799 MTV1.0020.6310.9990.788 TLG1.0000.8970.9990.478Note. *CA19--9* carbohydrate antigen 19--9, *CA72--4* carbohydrate antigen 72--4, *CEA* carcinoembryonic antigen, *WDA* well differentiated adenocarcinoma, *MDA* moderate differentiated adenocarcinoma, *PDA* poorly differentiated adenocarcinoma, *SRC* signet-ring cell carcinoma, *MAC* mucinous adenocarcinoma, *PET/CT* positron emission tomography/computed tomography, *SUV* standardized uptake value, *Max* maximum, *MTV* metabolic tumor volume, *TLG* total lesion glycolysis, *PFS* progression free survival, *OS* overall survival, *HR* hazards ratio. ^a^, reference group

When stratifying the patients according to c-MET-expression status, univariate analysis showed that in patients with c-MET-positive cancers, SUV~max~, SUV~peak~, MTV, and TLG all correlated significantly with PFS (HR = 1.054, 1.068, 1.009 and 1.001, respectively; *P* = 0.037, 0.034, 0.013 and 0.012, respectively), and OS (HR = 1.063, 1.079, 1.015 and 1.002, respectively; *P* = 0.013, 0.012, 0.001 and 0.001, respectively; Table [4](#Tab4){ref-type="table"}). However, in patients with c-MET-negative cancers, neither PFS nor OS correlated with any of the semi-quantitative PET parameters (Table [4](#Tab4){ref-type="table"}). In multivariate analysis, as shown in Table [5](#Tab5){ref-type="table"}, SUV~max~ and SUV~peak~ did not correlate with patients' outcomes, neither with PFS nor with OS. However, MTV and TLG were independent factors in predicting the patients' OS (HR = 1.009 and 1.003, respectively; *P* = 0.024 and 0.021, respectively) after correction for distant metastasis; however, these associations were not significant for PFS (HR = 1.005 and 1.001, respectively; *P* = 0.274 and 0.350, respectively).Table 5Multivariate linear COX regression assessing associations between parameters from ^18^F-FDG PET/CT and prognosis in patients with positive c-Met expressionVariablesPFS^b^PFS^c^OS^b^OS^c^HR*P*HR*P*HR*P*HR*P*Findings on PET/CT Distant metastasis5.620\<  0.0015.650\<  0.0013.0260.0023.1510.002 Locoregional^a^1.0001.0001.0001.000SUV~max~0.8190.5820.7880.5101.3060.5301.2680.486SUV~peak~1.3130.5581.3720.4980.7270.5520.7610.537MTV1.0050.2741.0090.024TLG1.0010.3501.0030.021Note. *PET/CT* positron emission tomography/computed tomography, *SUV* standardized uptake value, *Max* maximum, *MTV* metabolic tumor volume, *TLG* total lesion glycolysis, *PFS* progression free survival, *OS* overall survival, *HR* hazards ratio. ^a^, reference group. ^b^ This model used MTV, not TLG. ^c^ This model used TLG, not MTV

Discussion {#Sec13}
==========

In this study, we investigated the prognostic values of semi-quantitative parameters on ^18^F-FDG PET/CT in patients with advanced gastric cancer according to their expression status of c-MET. The volumetric parameters of gastric cancer in situ*,* in terms of MTV and TLG, correlated significantly with positivity of c-MET expression. In addition, significant associations between volumetric parameters and the patients' survival outcomes were identified in patients with c-MET-positive tumors, but not in patients with c-MET-negative tumors. Furthermore, the volumetric parameters, including MTV and TLG, had prognostic value in predicting the survival outcomes of patients with c-MET-positive gastric cancers.

PET/CT has the advantage of quantitatively assessing tumor metabolism using various semi-quantitative parameters, among which the SUV~max~ from a single pixel anywhere within the tumor is the most commonly used. More novel and robust is the SUV~peak~, which represents the highest mean SUV from a fixed spherical VOI centered over the highest metabolic part of the tumor. However, these parameters are two dimensional, and cannot accurately reflect the whole metabolic activity of the tumor. In contrast, volume-based parameters, such as MTV and TLG, evaluate global volume and metabolism. Previous studies have demonstrated that MTV and TLG had excellent sensitivity and specificity to predict survival outcomes of patients with cancer \[[@CR17], [@CR18]\]. In the present study, we found that volumetric MTV and TLG were superior to SUV~max~ and SUV~peak~ to predict the survival of patients with gastric cancer. These results were consistent with those from a study by Park et al. \[[@CR5]\].

The activation of the c-Met/HGF pathway plays an important role in the tumorigenesis of gastric cancer \[[@CR19]\]. Overexpression of c-MET has been proven to indicate poor prognosis in patients with gastric cancer \[[@CR7], [@CR8]\]. In the current study, among patients with c-MET positive gastric cancer, those who had higher tumor volumetric parameters presented a significantly shorter OS than those with lower volumetric parameters. However, this association was negative in patients with c-MET-negative gastric cancers. This suggested that the volumetric parameters on PET/CT might serve as a tool to stratify patients with gastric cancer for potential c-MET targeting therapy. The results may provide useful indications to clinicians, given that many clinical trials on c-MET targeting agent are ongoing \[[@CR10], [@CR12]\]. However, the volumetric parameters were not independently associated with PFS in patients with c-MET-positive cancer. This might be because of the small sample of patients included in the study and that none of these patients received any c-MET targeting therapy.

In the univariate analyses, both SUV~max~ and SUV~peak~ were significantly associated with patients' outcomes, either with PFS or with OS, in patients with c-MET positive cancers; however, in multivariate analyses, these associations were not significant. This might be related to the collinearity of SUV~max~ and SUV~peak~ with the volumetric parameters, given that tumors with high SUV~max~ and SUV~peak~ tended to have large MTV and TLG \[[@CR20], [@CR21]\]. Nevertheless, the highest metabolic focus within a tumor (SUV~max~) and the metabolism of the central areas around it (SUV~peak~) may not always be associated with a large tumor burden of the primary site. This might explain why the volumetric parameters, but not SUV~max~ or SUV~peak~, were identified as independent factors to predict patients' survival outcomes in the multivariate analyses.

There are many methods for volume segmentation, including gradient-based method, the adaptive threshold method (based on signal-to-background ratio (SBR)), and the relative or absolute SUV threshold method \[[@CR22]--[@CR26]\]. The gradient-based method is much more complex than the threshold-based method, because complicated image processing is needed, including denoising, deblurring, gradient estimation, and watershed transformation \[[@CR23]\]. Errors can accumulate during the image-processing steps. Therefore, it is not suitable for use clinically in most PET workstations. The adaptive threshold method proposed by Daisne et al. \[[@CR27]\] has inherent limitations for gastric cancer. First, the method relies on a calibration curve, which was validated in sphere phantoms with symmetrical volumes, homogeneous activity, and sharp demarcation. However, gastric cancers always have complex shapes and heterogeneous radioactivity levels. Second, the adaptive threshold method involves estimating the SBR assuming that the background activity is uniform. Small variations in the background activity may influence the SBR and the volume measured. The gastric wall has a wide variation of background metabolism, because of physical uptake or inflammation. Therefore, we chose the fixed-threshold method.

Gastric cancer has wide range of metabolic activity. Commonly, cancers can show low uptake of FDG, but are highly aggressive, such as poorly differentiated adenocarcinoma, signet-ring cell carcinoma, and mucinous adenocarcinoma. These tumors commonly present with low metabolic activity, even with SUV~max~ \< 2.5; therefore, the threshold of ≥2.5 for delineating tumor VOI cannot be used. Therefore, we chose the 40%-SUV~max~ threshold, which has been widely used in previous studies \[[@CR5], [@CR28]\]. However, clinical practice indicated that the percentage threshold relies strongly on the SUV~max~ of the tumor, leading to a large variance between cancer lesions with high FDG uptakes. A method using different thresholds for tumors with different metabolic levels has being used in a previous study \[[@CR5]\]. This method might have introduced bias to our study; however, it remains the most feasible one for use in gastric cancer.

Our study had several limitations. First, the diagnostic criteria for c-MET status were not standard. We analyzed c-MET only using protein overexpression assessed by immunohistochemical (IHC) staining. However, diagnostic criteria involving IHC have been used frequently in recent studies, because standard criteria have not been validated until now \[[@CR14], [@CR15], [@CR19]\]. Second, because of the retrospective nature of this study, the studied patients did not receive c-MET targeting therapy. We cannot guarantee that the same results would be produced if patients that experienced c-MET targeting therapy were studied. Therefore, large-scale clinical trials should be conducted using patients that experienced c-Met targeting therapy to study volumetric PET/CT parameters to predict prognosis in patients with gastric cancer patients in relation to c-MET expression. Third, because of the heterogeneity of patients, the discrepancy of received treatment, and the limited sample size of population, the result could only be interpreted within this study.

Conclusion {#Sec14}
==========

Gastric cancers that with positive c-MET expression had higher metabolic tumor volume and total lesion glycolysis compared with c-MET-negative gastric cancers. Volumetric parameters on ^18^F-FDG PET/CT may have a role in predicting prognosis of patients with c-MET-positive gastric cancer.
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